EUFOREUM Berlin 2023 : Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus
(2024) In Pediatric Allergy and Immunology 35(7).- Abstract
The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual forum EUFOREUM in Berlin in November 2023. The aim of EUFOREUM 2023 was to highlight pediatric action plans for prevention and optimizing care for type 2 inflammatory conditions starting in childhood, with a focus on early-stage diagnosis, ensuring neither under- nor overdiagnosis, optimal care, and suggestions for improvement of care. EUFOREA is an international not-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and... (More)
The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual forum EUFOREUM in Berlin in November 2023. The aim of EUFOREUM 2023 was to highlight pediatric action plans for prevention and optimizing care for type 2 inflammatory conditions starting in childhood, with a focus on early-stage diagnosis, ensuring neither under- nor overdiagnosis, optimal care, and suggestions for improvement of care. EUFOREA is an international not-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in the keynote lectures and faculty of the virtual EUFOREUM 2023 (www.euforea.eu/euforeum) coming from the pediatric, allergology, pulmonology, ENT, dermatology, primary health care fields and patients around the central theme of type 2 inflammation. As most type 2 inflammatory conditions may start in childhood or adolescence, and most children have type 2 inflammation when suffering from a respiratory or skin disease, the moment has come to raise the bar of ambitions of care, including prevention, remission and disease modification at an early stage. The current report provides a comprehensive overview of key statements by the faculty of the EUFOREUM 2023 and the ambitions of EUFOREA allowing all stakeholders in the respiratory field to be updated and ready to join forces in Europe and beyond. (Figure presented.).
(Less)
- author
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- AD, allergic rhinitis, asthma, EUFOREA, pediatrics, rhinosinusitis, T2-inflammation
- in
- Pediatric Allergy and Immunology
- volume
- 35
- issue
- 7
- article number
- e14183
- publisher
- Blackwell Munksgaard
- external identifiers
-
- scopus:85197603984
- pmid:38949196
- ISSN
- 0905-6157
- DOI
- 10.1111/pai.14183
- language
- English
- LU publication?
- yes
- id
- 580a13c6-b7ab-4e79-a2b3-9257f35cb7f8
- date added to LUP
- 2024-09-30 14:58:22
- date last changed
- 2025-04-29 10:36:48
@article{580a13c6-b7ab-4e79-a2b3-9257f35cb7f8,
abstract = {{<p>The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual forum EUFOREUM in Berlin in November 2023. The aim of EUFOREUM 2023 was to highlight pediatric action plans for prevention and optimizing care for type 2 inflammatory conditions starting in childhood, with a focus on early-stage diagnosis, ensuring neither under- nor overdiagnosis, optimal care, and suggestions for improvement of care. EUFOREA is an international not-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in the keynote lectures and faculty of the virtual EUFOREUM 2023 (www.euforea.eu/euforeum) coming from the pediatric, allergology, pulmonology, ENT, dermatology, primary health care fields and patients around the central theme of type 2 inflammation. As most type 2 inflammatory conditions may start in childhood or adolescence, and most children have type 2 inflammation when suffering from a respiratory or skin disease, the moment has come to raise the bar of ambitions of care, including prevention, remission and disease modification at an early stage. The current report provides a comprehensive overview of key statements by the faculty of the EUFOREUM 2023 and the ambitions of EUFOREA allowing all stakeholders in the respiratory field to be updated and ready to join forces in Europe and beyond. (Figure presented.).</p>}},
author = {{Conti, Diego M. and Vibeke, Backer and Kirsten, Beyer and Bjermer, Leif and Adam, Chaker and Stephanie, Dramburg and Mina, Gaga and Monika, Gappa and Philippe, Gevaert and Eckard, Hamelmann and Hellings, Peter W. and Milos, Jesenak and Kopp, Matthias V. and Marcus, Maurer and Marcia, Podesta and Dermot, Ryan and Scadding, Glenis K. and Eike, Wüstenberg and Ulrich, Wahn and Susanne, Lau}},
issn = {{0905-6157}},
keywords = {{AD; allergic rhinitis; asthma; EUFOREA; pediatrics; rhinosinusitis; T2-inflammation}},
language = {{eng}},
number = {{7}},
publisher = {{Blackwell Munksgaard}},
series = {{Pediatric Allergy and Immunology}},
title = {{EUFOREUM Berlin 2023 : Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus}},
url = {{http://dx.doi.org/10.1111/pai.14183}},
doi = {{10.1111/pai.14183}},
volume = {{35}},
year = {{2024}},
}